文献速递前列腺癌

MRI对不可逆电穿孔局灶治疗后持续存在前列腺癌的诊断价值

The diagnostic value of MRI for persistent prostate cancer following irreversible electroporation focal therapy.
PubMed 文献 · BJU Int · 2025-04-04

本文为多中心随机试验的事后分析,纳入106例局限性低至中危前列腺癌患者,随机接受局灶或扩大不可逆电穿孔(IRE)消融,术后6个月和12个月复查MRI,6个月行经会阴模板穿刺活检(TMB)。结果显示MRI检出治疗后持续临床显著前列腺癌的特异度较好但敏感度低,作者认为无论MRI结果如何都不应推迟重复TMB。

要点

  • MRI检出IRE治疗后持续临床显著前列腺癌的敏感度低(治疗区30%、未治疗区20%),特异度较高(均为91%)。
  • TMB检出治疗区和未治疗区临床显著前列腺癌的比例均为9.9%(10/101)。
  • 作者认为无论MRI结果如何,都不应推迟重复经会阴模板穿刺活检。

核心结论

  • MRI检测IRE治疗后持续存在的临床显著前列腺癌具有较好的特异度,但敏感度差。
  • 作者认为无论MRI结果如何,都不应推迟重复经会阴模板穿刺活检。

研究设计与样本

  • 本文为多中心随机试验的事后分析,纳入106例局限性低至中危前列腺癌男性,随机接受局灶或扩大IRE消融。
  • 全部患者在IRE后6个月和12个月复查MRI,并在IRE后6个月行经会阴模板穿刺活检(TMB)。
  • 其中101例患者在IRE后6个月完成了重复MRI扫描和前列腺穿刺活检。

主要发现

  • 106例中39例(37%)为临床不显著前列腺癌,67例(63%)为临床显著前列腺癌(国际泌尿病理学会分级≥2)。
  • TMB检出治疗区临床显著前列腺癌的比例为9.9%(10/101),未治疗区亦为9.9%(10/101)。
  • 治疗区MRI检出临床显著前列腺癌的敏感度为30%(95%CI 6.7%-65%)、特异度91%(95%CI 82%-96%)、阳性预测值27%(95%CI 6.0%-61%)、阴性预测值92%(95%CI 84%-97%)。
  • 未治疗区MRI检出临床显著前列腺癌的敏感度为20%(95%CI 2.5%-56%)、特异度91%(95%CI 82%-96%)、阳性预测值20%(95%CI 2.5%-56%)、阴性预测值91%(95%CI 82%-96%)。

关键数值与推荐

  • MRI检出治疗区临床显著前列腺癌:敏感度30%(95%CI 6.7%-65%),特异度91%(95%CI 82%-96%)。
  • MRI检出未治疗区临床显著前列腺癌:敏感度20%(95%CI 2.5%-56%),特异度91%(95%CI 82%-96%)。

临床怎么用

  • 作者认为无论MRI结果如何,都不应推迟重复经会阴模板穿刺活检。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the diagnostic value of magnetic resonance imaging (MRI) for persistent prostate cancer after irreversible electroporation (IRE) therapy. PATIENTS AND METHODS: This is a post hoc analysis from a multicentre randomised trial, in which men with localised low- to intermediate-risk prostate cancer were randomised to receive either focal or extended IRE ablation. All patients underwent repeat MRI scans at 6 and 12 months and transperineal template mapping biopsy (TMB) at 6 months post-IRE. The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of MRI were calculated for infield and outfield lesions using 2 × 2 contingency tables with 95% confidence intervals (CIs) for clinically significant prostate cancer and any-grade prostate cancer. RESULTS: A total of 106 patients were recruited to this study, including 39 patients (37%) with clinically insignificant prostate cancer and 67 patients (63%) with clinically significant prostate cancer (International Society of Urological Pathology grade ≥2). Of these, 101 patients underwent repeat MRI scan and prostate biopsy at 6 months after IRE. The rate of clinically significant prostate cancer detected by TMB infield and outfield was 9.9% (10/101) and 9.9% (10/101), respectively. In the treated area, the sensitivity, specificity, PPV and NPV for MRI to detect clinically significant prostate cancer were 30% (95% CI 6.7%-65%), 91% (95% CI 82%-96%), 27% (95% CI 6.0%-61%) and 92% (95% CI 84%-97%), respectively. In the untreated area, the sensitivity, specificity, PPV and NPV of MRI to detect clinically significant prostate cancer were 20% (95% CI 2.5%-56%), 91% (95% CI 82%-96%), 20% (95% CI 2.5%-56%) and 91% (95% CI 82%-96%), respectively. CONCLUSION: Favourable specificity but poor sensitivity was achieved with use of MRI to detect persistent clinically significant prostate cancer after IRE treatment. Repeat TMB should not be deferred, regardless of MRI results.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Zhang K, Teoh J, Laguna P, et al. The diagnostic value of MRI for persistent prostate cancer following irreversible electroporation focal therapy. BJU Int. 2025. PMID: 40183286. doi:10.1111/bju.16720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。